Ascentage Pharma Group International (NASDAQ:AAPG) Trading Down 6% - Should You Sell?

Key Points

• Ascentage Pharma shares fell 6% to about $17.19 in light trading, with volume down 64% from the average session.
• Despite the decline, analysts remain bullish: the stock has a consensus “Buy” rating and an average price target of $46.43, substantially above its recent price.
• The clinical-stage biotech reported a quarterly loss of $0.65 per share on $22.24 million in revenue, while analysts expect a full-year loss of $2.26 per share.

Shares of Ascentage Pharma Group International - Unsponsored ADR (NASDAQ:AAPG - Get Free Report) fell 6% on Monday . The stock traded as low as $17.19 and last traded at $17.1850. 2,433 shares traded hands during mid-day trading, a decline of 64% from the average session volume of 6,834 shares. The stock had previously closed at $18.28.

Wall Street Analysts Forecast Growth

AAPG has been the topic of several recent analyst reports. BTIG Research restated a "buy" rating and issued a $48.00 target price on shares of Ascentage Pharma Group International in a report on Friday, August 21st. B. Riley Financial started coverage on shares of Ascentage Pharma Group International in a report on Wednesday, June 10th. They set a "buy" rating and a $45.00 price target for the company. Finally, Raymond James Financial reissued a "buy" rating on shares of Ascentage Pharma Group International in a research report on Wednesday, June 10th. Two investment analysts have rated the stock with a Strong Buy rating and eight have assigned a Buy rating to the company. According to MarketBeat.com, the stock has a consensus rating of "Buy" and an average price target of $46.43.

Ascentage Pharma Group International Price Performance

The firm has a fifty day simple moving average of $18.23 and a two-hundred day simple moving average of $20.96. The company has a debt-to-equity ratio of 1.09, a current ratio of 1.22 and a quick ratio of 1.18.

Ascentage Pharma Group International (NASDAQ:AAPG - Get Free Report) last posted its earnings results on Wednesday, August 19th. The company reported ($0.65) earnings per share (EPS) for the quarter. The firm had revenue of $22.24 million during the quarter. As a group, research analysts expect that Ascentage Pharma Group International - Unsponsored ADR will post -2.26 earnings per share for the current year.

Institutional Inflows and Outflows

A number of hedge funds have recently added to or reduced their stakes in the stock. Citadel Advisors LLC purchased a new stake in shares of Ascentage Pharma Group International in the 3rd quarter worth about $383,000. Hsbc Holdings PLC purchased a new position in shares of Ascentage Pharma Group International during the second quarter valued at about $391,000. Finally, UBS Group AG increased its position in shares of Ascentage Pharma Group International by 149.4% during the third quarter. UBS Group AG now owns 18,345 shares of the company's stock valued at $716,000 after buying an additional 10,988 shares during the period.

Ascentage Pharma Group International Company Profile

Ascentage Pharma Group International is a clinical‐stage biopharmaceutical company focused on developing small‐molecule therapeutics that modulate programmed cell death pathways, including the Bcl‐2 family and the MDM2–p53 axis. Its pipeline features orally bioavailable inhibitors such as APG-2575, a selective Bcl-2 inhibitor, and APG-115, a potent MDM2 antagonist, both aimed at reactivating apoptosis in cancer cells across hematologic malignancies and solid tumors.

Founded in 2008 by biotechnology entrepreneur Dr.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source